Secondary Logo

Journal Logo

Amifostine Curtails Pathologic Alterations of Type I Collagen in an Irradiated Breast Reconstruction Model: A Raman Spectroscopic Analysis

Luby, Alexandra O. MS; Snider, Alicia E. MD; Mandair, Gurjit S. PhD; Lynn, Jeremy V. BS; Urlaub, Kevin M. BS; Nelson, Noah S. MPH; Donneys, Alexis MS, MD; Buchman, Steven R. MD

Plastic and Reconstructive Surgery - Global Open: August 2019 - Volume 7 - Issue 8S-1 - p 33-34
doi: 10.1097/01.GOX.0000584384.28466.86
Breast Abstracts
Best Abstract

University of Michigan, Ann Arbor, MI

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

OBJECTIVE: As indications for adjuvant radiation therapy (XRT) have expanded in recent years, an increasing number of breast cancer patients are receiving XRT as a component of treatment. Although XRT is highly effective, it often damages the skin and soft tissues of the breast. Radiation-induced damage to dermal type I collagen reduces cutaneous elasticity and strength, which can ultimately limit patient candidacy for expander-based breast reconstruction. In the present study, we utilized amifostine (AMF) as a prophylactic radioprotectant with the objective of mitigating dermal type I collagen injury associated with XRT. To investigate this, we utilized Raman spectroscopy to analyze the chemical properties of dermal type I collagen in a murine model of irradiated expander-based breast reconstruction.

METHODS: Female Lewis rats were grouped (n = 7/group): expander without XRT (Control); expander + XRT (XRT); and expander + AMF + XRT (AMF). Expanders were surgically placed in a submusculocutaneous plane on the dorsum of the animal and filled to achieve a final volume of 15 ml. Both the XRT and AMF group received a total XRT dose of 35 Gy. The AMF group received AMF pretreatment 30 minutes before XRT. After a 20-day recovery period, tissues overlying the expander were harvested and sectioned. Raman spectroscopy was performed to study the chemical properties of dermal type I collagen.

RESULTS: Based on the (853 + 877)/1,657 cm−1 band intensity ratio (Pro+Hyp/Amide-I ratio), collagen turnover was impaired in expanded, irradiated tissues (mean ratio, 0.492; SD, 0.086) compared to the control group (mean ratio, 0.660; SD, 0.089). This impaired collagen synthesis was not observed in animals receiving AMF pretreatment (mean ratio, 0.685; SD, 0.098), supporting its efficacy as a radioprotectant. Additionally, based on the 853/877 cm−1 band intensity ratio (Hyp/Pro ratio), the hydroxylation of proline within collagen was reduced in expanded, irradiated tissues compared to controls. This decrease in the Hyp/Pro ratio was paralleled and supported by the observed reduction in collagen synthesis (Pro+Hyp/Amide-I ratio). This reduction in hydroxylation of collagen proline was mitigated by AMF pretreatment. The 1,656/1,673 cm−1 intensity ratio (α-helix/β-sheet ratio) was evaluated to detect changes in collagen secondary structure, and interestingly, no significant changes in the α-helix/β-sheet ratio were found between irradiated and non–irradiated-expanded tissues. These results suggest that radiotherapy reduces collagen synthesis, but the integrity of collagen secondary structure is preserved.

CONCLUSION: This study further elucidated the mechanism of dermal type I collagen radiation injury. Pathologic changes in the chemical composition of irradiated tissues were detected utilizing Raman spectroscopy. Radiation significantly impaired collagen synthesis, resulting in a marked reduction in the collagen content of irradiated tissues. Amifostine was shown to mitigate these detrimental effects, as AMF pretreatment demonstrated a significant preservation in type I collagen synthesis in this model of irradiated expander-based breast reconstruction. Utilizing AMF as a prophylactic radioprotectant in breast cancer patients has the potential to increase reconstructive options available to patients and their plastic surgeons and improve surgical outcomes in the aftermath of radiotherapy.

Copyright © 2019 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. All rights reserved.